Sirona Biochem Announces CFDA Approval of SGLT2 Inhibitor

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
61
Sirona Biochem Announces CFDA Approval of SGLT2 Inhibitor for Phase I Clinical Trial

VANCOUVER, British Columbia, July 12, 2018 (GLOBE NEWSWIRE) -- Sirona Biochem Corp . (TSX-V: SBM ) (FSE:ZSB) (the “ Company ”) announced today that partner, Jiangsu Wanbang Biopharmaceuticals (“Wanbang”), has confirmed the Investigational New Drug (IND) submission to China’s Food and Drug Administration (CFDA) for its SGLT2 inhibitor was approved for clinical trial. Wanbang will be entering a Phase I clinical trial for the treatment of Type 2 diabetes. The CFDA approval triggers a $500,000 USD milestone payment to Sirona Biochem.

Sirona Biochem’s SGLT2 inhibitor, TFC-039, was licensed to Wanbang’s parent company, Shanghai Fosun Pharmaceuticals in 2014 with rights for China. Since the initial licensing agreement, Fosun Pharma has invested more than RMB 29 million toward the development of the SGLT2 inhibitor.

According to the International Diabetes Federation and the World Health Organization, China now has some of the highest rates of diabetes cases, affecting 110 million people, or 11% of the population. Over 90% of the cases are Type 2 diabetes.

“Wanbang has been very dedicated to this project and we are pleased to be advancing to the clinic with the compound,” said Dr. Howard Verrico, CEO. “With the surging rates of diabetes in China, there remains a need for new therapies. TFC-039 will be able to enter this market as a once-daily drug or add-on therapy for the many people struggling with this disease.”

About Jiangsu Wanbang Biopharmaceuticals

Jiangsu Wanbang Pharmaceuticals manufactures and sells a variety of products including those for chronic disease treatment, antibiotics, and other endocrine diseases. Parent company, Fosun Pharma, is a leader in the pharmaceutical industry and regarded as one of the top five domestic pharmaceutical companies in China.

About Sirona Biochem Corp. Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com .

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information regarding this press release, please contact:

Christopher Hopton, CFO Sirona Biochem Corp. Phone:  1.604.282.6064 Email: chopton@sironabiochem.com

---------------------------------------------

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise.  Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vail’s Board Fight Puts Strategy Under a Sharp Lens

Updated Category News Views 62

Fresh snow does not make a boardroom dispute disappear. Vail Resorts has put out an investor presentation ahead of its December 14, 2026 annual meeting, asking shareholders to support all nine of management’s director nominees on its white proxy card. That is the formal message. The real message is plainer: NYSE:MTN knows this election has become a test of whether...

Continue Reading
Color Me Mine Tests Florida's Creative Leisure Demand

Updated Category News Views 72

Pottery studios are not exactly the sort of thing that makes markets pound the table, but Florida’s latest Color Me Mine push deserves a closer look. The company signed three franchise agreements in 2026 for Panama City Beach, Doral and Boca Raton, adding planned growth to a state where it already operates 11 studios. For a private franchisor, this is not a quarterly...

Continue Reading
Peptide Labels Cannot Substitute for Clinical Care

Updated Category News Views 151

A Label Is Not a Care Plan Those three little words, research use only, carry far more weight than a flashy product page would have people believe. The HelloNation article featuring wellness expert Andres Giraldo makes a plain but necessary distinction: a research-use-only, or RUO, label does not turn a peptide into prescribed treatment, and it sure does not establish...

Continue Reading
Somerville’s New Immersive Bet Has Room to Grow Locally

Updated Category News Views 74

A passcard, a hidden door, and 12,000 square feet of mischief have landed at Somernova. Edge of Elsewhere, the new flagship attraction from Boston-area creative studio Midnight Mansion, is open in Somerville’s Union Square as of November 18, 2026. It is part interactive art installation, part puzzle game, part physical story world. That sounds delightfully odd, which is...

Continue Reading
Watson Motion Tests Military Pretrial Confinement Rules

Updated Category News Views 170

Military confinement fights are rarely neat, and this one comes with a short clock but plenty of unanswered questions. Defense lawyers for U.S. Air Force Maj. Jason Watson argued on Nov. 17 that he should be released from pretrial confinement while his case proceeds. A military judge is ordinarily expected to issue a ruling within 14 days of the hearing, under the court's...

Continue Reading
AI Gives CPA Firms a New Advisory Staffing Math Today

Updated Category News Views 75

Month-end just got a lot less comfortable for firms living on the clock. Netsurit and Southwestern Talent are pitching the Virtual CFO Platform as a way for CPA firms to turn machine-led analysis into advisory work without first building a costly bench of specialists. That is not a cute workflow tweak. It goes straight at the labor model that has kept plenty of accounting...

Continue Reading
Hanmi Compressor Tests Vietnam Before Wider Expansion

Updated Category News Views 175

Compressed air is the sort of factory necessity nobody brags about until it fails, and that is precisely why Hanmi Compressor’s Vietnam plan deserves a sober look. The Daegu-based specialist is not arriving with a grand export victory lap. It is still building the front door: a website, a promotional video, and a process for finding Vietnamese manufacturers and...

Continue Reading
Hitachi's Quiet Fusion Bet Is Really About Data Control

Updated Category News Views 69

Weeks of engineering work can vanish because one storage system hiccups, which is a rotten way to learn that data infrastructure belongs in the mission-critical column. Esteyco’s new environment, built with Hitachi Vantara and implemented by Quadrics Sistemas, is not a fusion breakthrough. It is the less glamorous machinery that keeps serious fusion research from...

Continue Reading
Emaar's Huspy Deal Brings Financing Into Home Sales

Updated Category News Views 87

Mortgage paperwork is nobody’s idea of luxury, yet it can wreck a property sale faster than a bad floor plan. Emaar Properties has partnered with Dubai-based Huspy to give its customers access to mortgage advice and financing comparisons from more than 20 UAE banks. It is not a flashy tower launch or a headline-grabbing land purchase. Frankly, that is why investors...

Continue Reading
RayNeo's Black Friday Push Tests Smart Glasses Demand

Updated Category News Views 160

A million shipped pairs is a real milestone, but holiday markdowns are where the rubber meets the road for RayNeo. The company is taking its XR gaming glasses and iO AI smart glasses into Europe’s Black Friday scrum with discounts running through late November, betting that portability, giant virtual screens and a little AI convenience can pry open consumers’ wallets....

Continue Reading

Top 5 Most Recently Viewed Articles

How the Bank of England's Interest Rate Decision Impacts Your Investments

Updated Category Economy Views 316

Introduction The Bank of England's decision on interest rates plays a critical role in shaping the economic landscape, with far-reaching effects on your investment portfolio. Changes in these rates can influence stock market performance, affect bond yields, and alter the attractiveness of various asset classes. Understanding how these adjustments can impact your...

Continue Reading
Eric Beightel Joins Environmental Science Associates Team

Updated Category News Views 131

Eric Beightel Appointed as Federal Strategy Director Environmental Science Associates (ESA) is thrilled to welcome Eric Beightel to its team as the new Federal Strategy Director. With a comprehensive background in environmental policy, Beightel brings a wealth of knowledge to ESA, poised to enhance its capabilities in navigating the complexities of federal regulations....

Continue Reading
iBio Inc. Showcases Innovative Antibody Developments Soon

Updated Category News Views 257

Exciting Presentations from iBio Inc. iBio, Inc. (NASDAQ: IBIO), a pioneering biotechnology company, is gearing up to present breakthrough research on its Activin E antibody. This development showcases its commitment to addressing critical health challenges like obesity. Recently, Cory Schwartz, Ph.D., the Director of Research and Early Development at iBio, announced his...

Continue Reading
Turkey's Markets Experience A Dip as Investors React

Updated Category News Views 319

A Dip in Turkey's Stock Market Performance Turkey's stock market witnessed a decline recently, with shares closing lower on the exchange. The BIST 100 index, a benchmark for investors, finished down by 0.60%, indicating a challenging trading day for stakeholders. Sectors Impacting Market Trends Leading the Declines A noticeable drop in market values was driven by several...

Continue Reading
Medline Celebrated for Innovation in Respiratory Care Solutions

Updated Category News Views 180

Medline secured the prestigious Zenith Award from the American Association for Respiratory Care (AARC) in 2024, marking a significant moment for traders and healthcare pros alike. This award wasn’t just handed out; it was earned by only eight companies out of over 300 nominees. The kind of spotlight that draws attention can shake up market sentiments. Why Medline Stood...

Continue Reading